N-acetyl methionine

Other Names

(2RS)-2-(acetylamino)-4-(methylsulfanyl)butanoic acid(2S)-2-(acetylamino)-4-(methylsulfanyl)butanoic acid(2S)-2-acetamido-4-(methylsulfanyl)butanoic acid(2S)-2-acetamido-4-(methylthio)butanoic acid2-(acetylamino)-4-(methylthio)butanoic acid2-acetamido-4-(methylsulfanyl)butanoic acid2-acetamido-4-(methylthio)butanoic acidAc-DL-Met-OHAc-Met-OHAcetyl-DL-methionineAcetyl-L-methionineAcetylmethionineDL-AcetylmethionineDL-Methionine, N-acetyl-DL-N-AcetylmethionineL-(N-Acetyl)methionineL-Methionine, N-acetyl-L-N-AcetylmethionineMethionamineMethionine, N-acetyl-N-Ac-DL-MetN-Ac-L-MetN-Acetyl-D,L-MethionineN-Acetyl-D-methionineN-Acetyl-DL-methionineN-Acétyl-L-méthionineN-Acetyl-L-methionineN-AcetylmethioninN-AcetylmethionineN-AcétylméthionineNAMThiomedon

Synopsis

N-Acetyl Methionine: A Comprehensive Encyclopedic Reference

1. Identity, Chemical Characterization, and Common Forms

1.1 Nomenclature and Chemical Identity

N-acetyl methionine (abbreviated NAM or N-AcMet) refers most precisely to N-acetyl-L-methionine, the biologically relevant L-stereoisomeric form. Its molecular formula is C₇H₁₃NO₃S, and its PubChem CID is 448580. The compound is also known under the names Ac-Met-OH, acetylmethionine, and N-acetyl-L-methionine. Its CAS Registry Number is 65-82-7. The racemic mixture of both stereoisomers is designated N-acetyl-DL-methionine (PubChem CID 6180, CAS 1115-47-5).

N-acetyl-L-methionine is a chemically modified form of L-methionine, an essential amino acid, featuring an acetyl group attached to the amino nitrogen. The compound's molecular weight is approximately 190.24 g/mol.

1.2 Natural Occurrence

Although N-acetyl methionine has historically been thought of primarily as a synthetic derivative, research has demonstrated that it is an endogenous molecule. NAM is present in both human and mouse tissues and cells in culture, including a wide variety of cultured cells and brain derived cell types, as well as mouse and human brain tissue. Methionine is rapidly acetylated to form NAM in cultured human oligodendroglioma cells, with an initial rate of 0.44 ± 0.064 atom percent excess per minute.

N-acetyl methionine also arises naturally during protein metabolism. N-acetylmethionine is the immediately released product from the amino terminus of certain actin isoforms during protein processing. This reflects the broader biological phenomenon that N-terminal acetylation of proteins is a widespread and highly conserved process.

1.3 Common Forms and Preparations

N-acetyl methionine is commercially available in several forms:

N-acetyl-L-methionine: The pure L-stereoisomer, which possesses full biological activity as a methionine source.
N-acetyl-DL-methionine: The racemic mixture, containing both L- and D-forms. This has been studied primarily in ruminant animal nutrition contexts, where partial rumen bypass is sought.

N-acetyl-L-methionine is produced by reacting L-methionine with acetic anhydride in the presence of aqueous alkali, and it is useful as a nutritional additive. The process of acetylation of L-methionine in concentrated acetic acid using acetic anhydride has been documented in classical amino acid chemistry literature. N-acetylmethionine, as a derivative of methionine, has similar efficacy to methionine, but it can reduce methionine-specific flavors and can be added in a larger amount compared to methionine when added to foods.

2. Historical and Traditional Use

2.1 Early Research Context and Nutritional Science

N-acetyl methionine does not have a documented tradition of use within classical herbal or folk medicine systems. Unlike many dietary supplements derived from botanicals, NAM is a synthetic derivative of a natural amino acid, and its identity and study emerged from the development of nutritional biochemistry in the twentieth century. The history of its use is therefore scientific and industrial rather than ethnopharmacological.

Its earliest documented applications arose from research into food protein fortification. N-acetylmethionine can reduce methionine-specific flavors and can be added in larger amounts compared to methionine when added to foods, making it attractive as a food-grade nutritional additive. Italian researchers in the 1960s specifically investigated the use of acetyl-methionine as a supplement for diets low in sulfur-containing amino acids, particularly in vegetable-based dietary contexts (Beneditti et al., 1968, as cited in Boggs 1978).

Acetylated derivatives of methionine, threonine, and lysine were studied to determine their utility in overcoming the inherent problems associated with each amino acid; N-acetyl-L-methionine and N-acetyl-L-threonine were found to be fully available to promote growth of rats. These findings, accumulated from the 1960s through the 1970s, laid the nutritional groundwork for considering NAM a viable methionine source for humans and animals. Utilization of N-acetyl-L-methionine by humans was also studied and shown to be as effective as methionine in improving the quality of vegetable proteins deficient in sulfur amino acids.

Despite the fact that N-acetyl methionine (NAM) supplementation has long been reported as a bioavailable source of methionine in humans and known to reduce liver toxicity after acetaminophen overdose, its cellular endogenous presence had, until recently, never been investigated. This comment from a 2011 peer-reviewed paper illustrates that the bioavailability data and the hepatoprotective observations predate modern cellular biology studies of the compound by several decades.

2.2 Pharmaceutical Applications Emerging from the Mid-Twentieth Century

The use of NAM in pharmaceutical preparations predates its formal study as a dietary supplement. Its application as a stabilizer for human serum albumin (HSA) infusion products, and as an adjunct in acetaminophen toxicity management, represent the two major established applications developed outside of pure nutrition research. These are addressed in detail under the relevant scientific evidence sections below.

3. Key Constituents and Active Compounds

N-acetyl methionine is a single, chemically defined small molecule rather than a multi-constituent botanical preparation. Its biological activity derives from several interrelated properties:

3.1 Relationship to L-Methionine

Methionine is an essential sulfur amino acid engaged in key cellular functions such as protein synthesis and is a precursor for critical metabolites involved in maintaining cellular homeostasis. NAM serves principally as a prodrug or bioavailable delivery form of L-methionine after enzymatic deacetylation in the body.

3.2 Deacetylation by Aminoacylase 1 (ACY1)

The primary metabolic step required to release free L-methionine from NAM is catalyzed by the enzyme aminoacylase 1. Aminoacylase 1 (ACY1; EC 3.5.1.14) is a homodimeric, cytosolic, zinc-metalloprotein and endogenous mammalian enzyme that has a role in the catabolism of N-terminally acetylated proteins and amino acids; it hydrolyzes N-acetylated derivatives of methionine, glutamine, serine, alanine, glycine, leucine, and valine. Preferred substrates of ACY1 are aliphatic amino acids with a short-chain acyl moiety, especially N-acetyl-methionine.

Aminoacylase 1 performs the final step in the breakdown of acetylated proteins by removing the acetyl group from certain amino acids, which can then be recycled and used to build other proteins. The physiological importance of this enzyme is illustrated by the consequences of its deficiency: without this enzyme's function, acetyl groups are not efficiently removed from a subset of amino acids including methionine, glutamic acid, alanine, serine, glycine, leucine, valine, threonine, and isoleucine during the breakdown of proteins, and excess N-acetylated amino acids are released in urine.

In in vitro reactions of small intestine and liver extracts, approximately 46% of N-acetyl-DL-methionine was converted into L-methionine by intestinal extracts and approximately 50% by liver extracts. The digestive degradation rate of the L-form is significantly higher compared to the D-form among optical isomers.

3.3 Downstream Metabolic Pathways

Once deacetylated to free L-methionine, NAM participates in all methionine-dependent biochemical pathways. Methionine is converted to S-adenosylmethionine (SAMe) by the enzyme methionine adenosyltransferase (MAT) using ATP as co-substrate; two main MAT isoforms are expressed in the liver, with MATIII activated by methionine. SAMe's methyl group is transferred to a large variety of substrates — DNA, RNA, proteins, phosphatidylethanolamine, glycine, and guanidinoacetate — in reactions called transmethylation reactions, catalyzed by specific methyltransferases.

The transsulfuration pathway (TSP) is closely linked to methionine metabolism, which involves the conversion of methionine to homocysteine. Homocysteine may be remethylated to regenerate methionine, or enter the transsulfuration pathway to be converted first to cystathionine, and then to cysteine and α-ketobutyrate. Cysteine is transformed into a variety of sulfur-containing molecules, such as glutathione (GSH), taurine, sulfate, and hydrogen sulfide.

Methionine metabolism is the pivot linking the folate cycle to the transsulfuration pathway. In addition to being a precursor for glutathione synthesis and the principal methyl donor for nucleic acid, phospholipid, histone, biogenic amine, and protein methylation, methionine metabolites can participate in polyamine synthesis.

3.4 Direct Antioxidant Properties

Independent of its role as a methionine prodrug, NAM itself demonstrates direct antioxidant activity. N-acetyl-L-methionine (N-AcMet) was found to be a superior reactive oxygen species (ROS) scavenger. N-AcMet is an efficient stabilizer of albumin structure exposed to ROS. This reactivity with oxidizing species appears to be fundamental to its role as a pharmaceutical stabilizer (see Section 5.2).

The reason for using N-AcMet in this respect is that methionine itself is susceptible to oxidation by almost all forms of reactive oxygen species, allowing it to act as a sacrificial antioxidant scavenger. This sulfur-based reactivity is a key biochemical property of the molecule.

4. Scientific Evidence by Area of Use

4.1 Bioavailability as a Methionine Source

Evidence type: Human studies and animal studies.

Utilization of N-acetyl-L-methionine by humans has been studied and shown to be as effective as methionine in improving the quality of vegetable proteins deficient in sulfur amino acids. N-acetyl-L-methionine had a methionine-sparing value of 100% and N-acetyl-D-methionine a value of zero in chick growth assays, confirming that the biological activity is entirely stereoisomer-specific. The L-form was also observed to be fully effective as a methionine supplement when added to a methionine-deficient diet containing equal protein contributions from soybean, casein, and gelatin.

Limitations: The human studies establishing bioavailability equivalent to methionine are older (1970s–1980s) and relied primarily on nitrogen balance and protein quality measures rather than modern isotope tracer or plasma amino acid kinetics methodologies. No large, randomized controlled clinical trials in humans have been conducted specifically to quantify NAM's bioavailability parameters under contemporary standards.

4.2 Hepatoprotection in Acetaminophen Overdose

Evidence type: Preclinical reports; human clinical case observations cited in review literature.

N-acetyl methionine (NAM) supplementation has long been reported as a bioavailable source of methionine in humans and known to reduce liver toxicity after acetaminophen overdose. The mechanistic rationale for this application relates to methionine's role as a precursor to glutathione (GSH). When acetaminophen is taken in overdose, its reactive metabolite N-acetyl-para-benzoquinone imine (NAPQI) depletes hepatic GSH; replenishing methionine availability via NAM would theoretically restore GSH synthesis capacity and support hepatic detoxification. Cysteine, derived from methionine through the transsulfuration pathway, is transformed into glutathione (GSH), taurine, sulfate, and hydrogen sulfide.

Important context: In current clinical practice, N-acetylcysteine (NAC — a distinct compound from NAM) is the established and FDA-approved antidote for acetaminophen overdose. The available human evidence specifically for NAM in this indication is described in the literature as a long-standing observation rather than from formal randomized controlled trials. The mechanistic plausibility is clear, but NAM is not clinically established for this indication in the way NAC is.

4.3 Pharmaceutical Application: Stabilization of Human Serum Albumin (HSA) Products

Evidence type: Multiple in vitro and preclinical mechanistic studies; laboratory-based pharmaceutical research.

One of the most thoroughly characterized applications of N-acetyl-L-methionine in the published literature is its use as a stabilizer for albumin infusion preparations. Sodium octanoate and N-acetyl-L-tryptophan (N-AcTrp) are widely used as stabilizers during pasteurization and storage of albumin products; however, exposure to light photo-degrades N-AcTrp with the formation of potentially toxic compounds.

A 2007 study published in a pharmaceutical sciences journal by Anraku and colleagues validated N-AcMet as a new albumin stabilizer. N-AcTrp has a possible side effect of intracerebral disease; to provide safe and risk-free albumin products, N-acetyl-methioninate (N-AcMet) was validated as a new stabilizer. The effect of N-AcMet on oxidation was examined using AAPH as an oxidizing agent; carbonyl content in the presence of N-AcMet was significantly decreased. The co-use of N-AcMet and octanoate produces an excellent stabilizing effect on albumin and depresses agglomeration safely and without any risk of side effects.

Subsequent studies confirmed and extended these findings. A 2014 publication in Biochimica et Biophysica Acta demonstrated that N-AcMet is an effective stabilizer of albumin during photo-irradiation, while N-AcTrp promotes photo-oxidative damage to albumin. A 2016 study in Biochemistry and Biophysics Reports extended this to post-translational oxidation: the number of chemical modifications and structural changes in recombinant human serum albumin (rHSA) were significantly smaller in the presence of N-AcMet than N-AcTrp; the anti-oxidant properties of oxidatively stressed rHSA were best protected by adding N-AcMet; and N-AcMet was superior in preserving the normal pharmacokinetics of rHSA. N-AcMet is thus superior to N-AcTrp in protecting albumin preparations against oxidation.

The authors of the 2016 study proposed that N-AcMet should be useful as a new and effective stabilizer and antioxidant for albumin isolated from blood, rHSA, albumin-fusion proteins, and for preparations of rHSA-therapeutic complexes.

Strength of evidence for this application: Moderate — consistent across multiple independent laboratory research groups using rigorous biochemical and biophysical methods. Evidence is primarily preclinical (in vitro and murine pharmacokinetic models); the transition to routine clinical albumin manufacturing use would require regulatory and additional clinical validation. However, the mechanistic findings are robust.

4.4 Brain Biochemistry and Neurological Considerations

Evidence type: Cell culture and ex vivo human/mouse brain tissue studies.

A 2011 study published in the Journal of Neurochemistry (Smith et al.) was the first to systematically investigate NAM's endogenous presence in the nervous system. N-acetyl methionine supplementation has long been reported as a bioavailable source of methionine in humans; NAM was demonstrated to be present in both human and mouse tissues and cells in culture, including a wide variety of cultured cells, a number of brain-derived cell types, and mouse and human brain tissue. The presence of measurable quantities of NAM in brain cells in combination with its rapid formation points to a potential physiological role for N-acetylated methionine in the brain.

Additional indirect relevance comes from the role of the deacetylating enzyme ACY1 in neurological function. ACY1 is expressed by various tissues, particularly the brain and kidney, and has been identified as a risk locus at schizophrenia and bipolar disorder. Mutations in ACY1 cause aminoacylase 1 deficiency, an extremely rare metabolic disorder marked by central nervous system defects and increased urinary excretion of N-acetylated amino acids.

Strength of evidence: Weak to preliminary for any specific neurological application of supplemental NAM. The observations establish endogenous presence and enzymatic context but do not constitute evidence for a clinical benefit of exogenous NAM supplementation in any neurological condition. No human clinical trials in neurological conditions have been conducted.

4.5 Ruminant Animal Nutrition and Lactation (Animal Studies)

Evidence type: Controlled animal feeding trials; not directly applicable to human supplementation, but relevant to mechanistic understanding and to ruminant veterinary nutrition.

In animals having a rumen, when methionine is used as a feed additive, it is first used by rumen microorganisms and thus is not absorbed by the animals, whereas N-acetylmethionine is a rumen-protected amino acid that is absorbed after passing through the rumen and reaching the intestine.

A 2018 study in the Journal of Dairy Science (Fagundes et al.) examined production responses in eight lactating dairy cows supplemented with N-acetyl-L-methionine (NALM) in a 4×4 Latin square design. Trends were observed for increased fat-corrected milk yield/DMI and energy-corrected milk yield/DMI; positive effects were greater under adequate metabolizable protein diet conditions. Dietary treatments had similar effects on ruminal fermentation characteristics and microbial protein yield. Plasma methionine concentration increased under the MP-deficient but not the MP-adequate diet. Overall results suggest that NALM exerted a minor influence on ruminal metabolism but increased milk fat concentration, resulting in increases in milk fat yield and feed efficiency.

A 2019 study in the Journal of Dairy Science (Liang et al.) examined mid-lactation Holstein dairy cows supplemented with NALM. Lower plasma methionine concentration in cows receiving 60 g/d of NALM could be associated with higher metabolism efficiency in the liver of dairy cows under high NALM addition conditions. The protein content, fat content, milk protein, and fat yield were not improved by supplementation of NALM in this study.

A 2022 study in the Animal Science Journal (Fagundes et al.) used a 3×3 Latin square with six cows and compared ruminal versus abomasal infusion. Cows received a basal diet without NALM (control), or 30 g/day or 60 g/day of NALM by rumen placement; rumen NALM dosing led to a linear increase in plasma methionine concentration. Abomasal infusion with NALM resulted in both linear and quadratic increases in plasma methionine concentration. No NALM was detected in milk, liver, plasma, and muscle samples after rumen placement or abomasal infusion, indicating complete conversion to free methionine.

A 2022 study (Amaro et al., Journal of Dairy Science) assessed lactational performance. Supplementation of NALM at 15 or 30 g/head per day resulted in the greatest improvements in feed efficiency without affecting nitrogen metabolism of early- to mid-lactation dairy cows.

Strength of evidence in ruminants: Moderate — consistent findings across multiple controlled trials showing plasma methionine elevation and variable milk quality effects, with good mechanistic understanding of rumen bypass. These findings are not directly transferable to human nutrition but confirm the bioavailability principle.

4.6 Methylation, Gene Regulation, and Polyamine Synthesis

Evidence type: Established biochemistry of methionine/SAMe pathway; indirect relevance only for NAM specifically.

N-acetyl-L-methionine, through its conversion to free methionine and subsequently SAMe, is involved in the methylation of DNA, RNA, proteins, and lipids, playing a role in the regulation of gene expression and protein function. It also participates in the synthesis of polyamines, which are involved in cell growth and proliferation.

The initial step in transmethylation involves conversion of methionine to S-adenosylmethionine (SAM), which plays a significant role as a donor of methyl groups and is also involved in formation of polyamines such as spermidine. In mammals, in response to nutrient conditions, the liver plays a significant role in regulating methionine concentrations by altering its flux through the transmethylation, transsulfuration, and transamination metabolic pathways.

Strength of evidence: These mechanisms are established for the parent compound L-methionine and its downstream metabolite SAMe. As NAM is a quantitatively complete bioavailable source of methionine, these pathways are mechanistically relevant, but no clinical trials have specifically studied NAM's effects on methylation status, epigenetics, or polyamine synthesis in humans.

5. Body Systems and Health Areas Associated with N-Acetyl Methionine

5.1 Hepatic (Liver) System

The liver is the primary site of methionine metabolism. Methionine metabolism disorder can aggravate damage in the pathological state of a disease; in the occurrence and development of chronic liver diseases, changes in various components involved in methionine metabolism can affect the pathological state through various mechanisms. NAM's reported role in reducing liver toxicity in acetaminophen overdose contexts, and its contribution to hepatic GSH via the transsulfuration pathway, makes the liver a central target organ of interest.

5.2 Cardiovascular and Plasma Protein Systems

As described in Section 4.3, NAM has been extensively studied as a stabilizer for serum albumin — the most abundant circulating plasma protein. Human serum albumin (HSA) is the most abundant circulating plasma protein. NAM's capacity to scavenge ROS and protect albumin's tertiary structure has direct pharmaceutical relevance to intravenous albumin infusion therapy used in hypoalbuminemia, cirrhosis, and other conditions.

5.3 Nervous System

The presence of measurable quantities of NAM in brain cells in combination with its rapid formation point to a potential physiological role for N-acetylated methionine in the brain. N-acetyl-L-methionine is involved in the regulation of neurotransmitter levels and the modulation of synaptic plasticity in the central nervous system through its role as a methionine/SAMe precursor. However, direct human clinical evidence for neurological benefit of NAM supplementation is absent.

5.4 Cellular Redox and Antioxidant Defense

At the cellular level, N-acetyl-L-methionine contributes to the maintenance of redox balance and the detoxification of reactive oxygen species through both direct ROS scavenging by its sulfur moiety and through augmenting the methionine → cysteine → glutathione biosynthesis pathway. Methionine is a crucial metabolite that influences redox homeostasis through sulfur metabolism and the transsulfuration pathway.

5.5 Musculoskeletal and Growth Systems

Methionine is the universal initiating amino acid for protein synthesis in eukaryotic cells. Methionine is used as the first (N-terminal) amino acid during translation and can often be a limiting factor in protein synthesis, especially under conditions of methionine deficiency. NAM, as a full methionine-equivalent source, would therefore support all protein-synthetic processes in states of methionine deficiency.

6. Dosage Forms and Dosages Reported in Studies

The dosages of N-acetyl methionine reported in the literature vary considerably by context (human nutrition, pharmaceutical, veterinary). The following dosages are reported directly from cited sources:

Ruminant/dairy animal studies (not human dosing): 30 g/day and 60 g/day of NALM by rumen placement were studied in lactating dairy cows in a replicated 3×3 Latin square design.
Ruminant/dairy animal studies (lactation performance): NALM at 15 or 30 g/head per day resulted in the greatest improvements in feed efficiency in early- to mid-lactation dairy cows.
Pharmaceutical albumin stabilization context: Dosages are formulation-specific and expressed as concentrations in albumin solution rather than as supplemental doses to individuals.

No published human clinical trials specifically define an oral supplemental dosage range for N-acetyl-L-methionine used as a standalone human dietary supplement. The older human bioavailability studies (Boggs 1978, as cited in the literature) established equivalence to methionine in the context of protein quality improvement but did not establish therapeutic supplemental doses. Any human supplemental dose ranges circulating in the commercial supplement industry cannot be verified against peer-reviewed clinical literature and are therefore omitted here.

7. Safety Considerations and Interactions

7.1 Stereoisomer-Specific Activity and Relative Toxicity

Isosulfurous levels of excess L-methionine or N-acetyl-L-methionine were equally growth depressing in chick assays, but L-methionine elevated spleen iron deposition to a greater extent than N-acetyl-L-methionine. N-acetyl-D-methionine in excess depressed growth only slightly, due entirely to a depression in voluntary food intake, and no evidence of splenic hemosiderosis was observed from this addition. This suggests that, at excess doses, N-acetyl-L-methionine may have a marginally improved safety profile relative to free L-methionine with respect to iron-related organ toxicity, though both are growth-inhibiting at excess levels.

7.2 Methionine Excess and Hyperhomocysteinemia

Because NAM is a bioavailable source of L-methionine, the risks associated with methionine excess are relevant. Excess methionine intake is toxic, leading to hyperhomocysteinemia. When methionine is consumed in excess, it causes pathophysiological effects on the liver including cell injuries and dysfunction through hyperhomocysteinemia, which mediates cellular oxidative stress by generation of intracellular reactive oxygen species via homocysteine autoxidation. These toxicity concerns apply to the parent amino acid upon which NAM's biological activity depends. Individuals with pre-existing disorders of methionine metabolism, such as homocystinuria (CBS deficiency), would be particularly vulnerable to augmented methionine intake.

7.3 Aminoacylase 1 (ACY1) Deficiency

In individuals with the rare inborn error of metabolism caused by ACY1 deficiency, exogenous N-acetyl methionine would not be efficiently deacetylated. Children with genetic deficiency of ACY1 were identified through organic acid analyses revealing increased urinary excretion of several N-acetylated amino acids, including the derivatives of methionine, glutamic acid, alanine, leucine, glycine, valine, and isoleucine. Mutations in ACY1 cause aminoacylase 1 deficiency, an extremely rare metabolic disorder marked by central nervous system defects and increased urinary excretion of N-acetylated amino acids. In such individuals, supplemental NAM would accumulate rather than be converted to free methionine, with uncertain consequences.

7.4 Chemical Safety Classification

No component of N-acetyl-L-methionine at levels ≥0.1% is identified as a probable, possible, or confirmed human carcinogen by IARC. Formal toxicological studies with established RTECS data are not available in the public literature; the compound's safety profile in humans at supplemental doses has not been characterized through formal clinical toxicology studies. The available chemical safety data sheet notes that specific target organ toxicity data are not available.

7.5 D-Isomer Considerations in Racemic Preparations

The racemic N-acetyl-DL-methionine form, used in some veterinary and food applications, delivers only the L-component as a biologically effective methionine source. N-acetyl-L-methionine had a methionine-sparing value of 100% and N-acetyl-D-methionine a value of zero. Therefore, racemic preparations provide approximately half the methionine equivalent of a pure L-form preparation on a molar basis, which has dosing implications for applications targeting a specific methionine yield.

7.6 Interactions with Albumin-Binding Pharmacology

In the pharmaceutical context of albumin infusion products, the choice of stabilizer has potential clinical pharmacokinetic implications. In 25 patients who received albumin via an inline infusion filter that depleted stabilizers, there was an improvement of albumin binding, and there was less deterioration of circulating blood volume and renal function in comparison with a control group. This observation, while primarily relevant to intravenous albumin administration rather than oral NAM supplementation, illustrates that stabilizers bound to albumin can influence its binding function. The presence of N-AcMet improves the pharmacokinetics of ROS-exposed albumin.

Summary of Evidence Quality

N-acetyl methionine is a well-characterized chemical entity with established biochemistry as a methionine prodrug. Its bioavailability equivalence to L-methionine has been documented in both animal and human nutritional studies. Its role as an endogenous molecule in the brain has been demonstrated. Its pharmaceutical application as an albumin stabilizer is supported by multiple rigorous in vitro and preclinical studies. Its application in ruminant nutrition (rumen-protected methionine delivery) is supported by several controlled animal feeding trials. However, no large randomized controlled human clinical trials have been published for any specific health indication related to oral dietary supplementation in humans. The mechanistic science is robust, but the clinical evidence base for human supplementation applications specifically is currently weak to absent. Claims extrapolated from the established biochemistry of L-methionine and SAMe, while scientifically plausible, have not been directly validated for NAM as a supplement in controlled human trials.

References

Health Conditions

Health conditions that N-acetyl methionine may help support.

No conditions available.

Body Systems

Body systems that N-acetyl methionine may help support.

No body systems available.